Table 1.
Clinicopathological characteristics of the study patients.
| Variables | N=369 |
|---|---|
| Mean age (year) | 67.3 ± 10.8 |
| Male | 285 (77.2%) |
| Mean BMI (kg/m2) | 23.6 ± 3.7 |
| ASA | |
| 1-2 | 338 (91.6%) |
| ≥3 | 31 (8.4%) |
| Mean Charlson comorbidity index | 0.7 ± 0.9 |
| Clinical T stage | |
| ≤T2 | 335 (90.8%) |
| ≥T3 | 34 (9.2%) |
| Clincal N stage | |
| N0 | 320 (86.7%) |
| N+ | 49 (13.3%) |
| Clincal M stage | 3 (0.8%) |
| M0 | 366 (99.2%) |
| M1 | 3 (0.8%) |
| Operation type | |
| ORC | 289 (78.3%) |
| RARC | 80 (21.7%) |
| Diversion type | |
| Neobladder | 256 (69.4%) |
| Conduit | 107 (29.0%) |
| Continent cutaneous | 6 (1.6%) |
| Pathologic T stage | |
| ≤T2 | 239 (64.7%) |
| ≥T3 | 130 (35.3%) |
| Pathologic N stage | |
| N0 | 307 (83.2%) |
| N+ | 62 (16.8%) |
| Lymphovascular invasion | 77 (20.9%) |
| Adjuvant chemotherapy | 58 (15.7%) |
| G-C | 51 (13.9%) |
| DDMVAC | 3 (0.8%) |
| Others | 4 (1.0%) |
| hCG | 1.9 ± 12.6 |
| hCG ≤5 | 351 (95.1%) |
| hCG >5 | 18 (4.9%) |
| CA 125 | 15.2 ± 28.6 |
| CA125 ≤35 | 350 (94.9%) |
| CA125 >35 | 19 (5.1%) |
| CEA | 6.9 ± 59.1 |
| CEA ≤20 | 362 (98.1%) |
| CEA>20 | 7 (1.9%) |
| CA19-9 | 46.1 ± 395.4 |
| CA19-9 ≤ 37 | 340 (92.1%) |
| CA19-9>37 | 29 (7.9%) |